AI주식인사이트AI Stock Insight
C

팬젠

222110KOSDAQ

53.0 / 100

Reference Date: 2026-10-23

Financial Score17.5 / 40
News Sentiment12.5 / 25
Momentum13.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Slightly up 4.4% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Panzen focuses on producing and selling biosimilar EPO drugs, offering CMO/CDO services, and developing biopharmaceuticals such as Factor VIII and Aflibercept. Its EPO product, approved in Malaysia, South Korea, the Philippines, Saudi Arabia, and Thailand, has expanded globally. The company's proprietary PanGen CHO-TECH™ technology enhances biopharmaceutical production efficiency through advanced cell line and process development.

Number of Employees

78people

Average Salary

57.7M KRW

Score Calculation Basis

Detailed Financial Score

PER
32.82Industry Average 15.000.0Point

2.2x industry avg (risky)

PBR
2.25Industry Average 1.201.0Point

1.9x industry avg (risky)

ROE
7.48Industry Average 8.002.5Point

Below industry avg

Debt Ratio
0.10Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲46.0% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲85.9% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -5.9% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (21%)

Current 4,980Won52-week high 7,34052-week low 4,330
1-month return4.0Point

1m +4.40% (slight rise)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0